AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19719817 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil/fentanyl/midazolam
Number of subjects: 67
Study 19719817 — intervention group
Group type: COMPARATOR
Intervention: Placebo/fentanyl/midazolam
Number of subjects: 67
Study 19719817 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil/remifentanil/propofol
Number of subjects: 67
Study 19719817 — intervention group
Group type: COMPARATOR
Intervention: Placebo/remifentanil/propofol
Number of subjects: 67
Study 18564958 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music intervention (60 minutes for 15 sessions, 1 or 2 times weekly)
Number of subjects: 26
Study 18564958 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 26
Study 16094908 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging (4LB)
Number of subjects: 200
Study 16094908 — intervention group
Group type: COMPARATOR
Intervention: Usual system of care (control)
Number of subjects: 200
Study 11915491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (250 micrograms) with albuterol (0.15 mg/kg) - three nebulizations
Number of subjects: 143
Study 11915491 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (0.15 mg/kg) - six nebulizations (control group)
Number of subjects: 143
Study 11915491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (250 micrograms) with albuterol (0.15 mg/kg) - three nebulizations followed by three additional albuterol nebulizations
Number of subjects: 143
Study 11915491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide with albuterol in children less than six years of age
Number of subjects: 143
Study 9440092 — intervention group
Group type: EXPERIMENTAL
Intervention: D-thyroxine 6 mg/d
Number of subjects: 30
Study 9440092 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 7879725 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute trance duration
Number of subjects: 95
Study 7879725 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning alertness
Number of subjects: 95
Study 7879725 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening alertness
Number of subjects: 95
Study 7879725 — intervention group
Group type: COMPARATOR
Intervention: Temperature and light
Number of subjects: 95
Study 2118299 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (angiography and angioplasty)
Number of subjects: 201
Study 2118299 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 201
Study 368823 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind method
Number of subjects: 0
Study 368823 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide experimentation with critical clinician assessment
Number of subjects: 0
Study 31126582 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Group
Number of subjects: 0
Study 31126582 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 28288636 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week Smartphone-Based Coronary Heart Disease Prevention (SBCHDP) programme
Number of subjects: 80
Study 28288636 — intervention group
Group type: COMPARATOR
Intervention: Health promotion websites
Number of subjects: 80
Study 26675051 — intervention group
Group type: EXPERIMENTAL
Intervention: FINDRISC questionnaire
Number of subjects: 772
Study 24784466 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar placement technique for eLRP and eRALP in patients with lower abdominal incision scars (Group 1)
Number of subjects: 57
Study 24784466 — intervention group
Group type: COMPARATOR
Intervention: Trocar placement technique for eLRP and eRALP in patients without previous surgeries (Group 2)
Number of subjects: 57
Study 22526730 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate 72 mg daily for 5 weeks
Number of subjects: 30
Study 22526730 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate flexible dosage up to 1.3 mg/kg body weight during 47-week open-label extension
Number of subjects: 30
Study 19602907 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis patients
Number of subjects: 205
Study 19602907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 205
Study 17690120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug daily
Number of subjects: 1829
Study 17690120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study 15070878 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy
Number of subjects: 0
Study 15070878 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin therapy
Number of subjects: 0
Study 12048274 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab as adjuvant therapy
Number of subjects: 119
Study 12048274 — intervention group
Group type: COMPARATOR
Intervention: Local laboratory testing
Number of subjects: 119
Study 12048274 — intervention group
Group type: EXPERIMENTAL
Intervention: Central HercepTest and central FISH assays
Number of subjects: 119
Study 9032531 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day antibiotic prophylaxis (cefuroxime or ciprofloxacin)
Number of subjects: 0
Study 9032531 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days antibiotic prophylaxis (cefuroxime or ciprofloxacin)
Number of subjects: 0
Study 9032531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8497383 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone succinate (Solu-Medrol)
Number of subjects: 56
Study 8497383 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone succinate (Solu-Medrol)
Number of subjects: 56
Study 3549319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cy) administered for not more than 6 months at a maximum dosage of 10 mg/kg for 2 months
Number of subjects: 0
Study 3549319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30658560 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss resilient women
Number of subjects: 50
Study 30658560 — intervention group
Group type: COMPARATOR
Intervention: Nonresilient women
Number of subjects: 50
Study 29573263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative intravenous (IV) methylprednisolone (MP) 125 mg
Number of subjects: 59
Study 29573263 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (C)
Number of subjects: 59
Study 24472058 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine plus hydroxyzine
Number of subjects: 24
Study 24472058 — intervention group
Group type: COMPARATOR
Intervention: levocetirizine monotherapy
Number of subjects: 24
Study 22249941 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5-25 mg/day)
Number of subjects: 51
Study 22249941 — intervention group
Group type: COMPARATOR
Intervention: Traditional Japanese diet
Number of subjects: 51
Study 17933744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience manipulation
Number of subjects: 0
Study 17933744 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 0
Study 16099227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent compression therapy for 2 hours a day for 6 months
Number of subjects: 37
Study 16099227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1 g daily) and Vitamin D (800 IU daily)
Number of subjects: 37
Study 14499318 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol 15 mg/day plus ethinyl estradiol 0.05 mg/day
Number of subjects: 32
Study 14499318 — intervention group
Group type: COMPARATOR
Intervention: haloperidol 15 mg/day plus placebo
Number of subjects: 32
Study 11005607 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 1% clindamycin solution
Number of subjects: 0
Study 11005607 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin solution (Klimicin T, Lek)
Number of subjects: 0
Study 8610864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural puncture with a 26-gauge Whitacre spinal needle (no drug injected)
Number of subjects: 40
Study 8610864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dural puncture)
Number of subjects: 40
Study 1357297 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks anticoagulation
Number of subjects: 712
Study 1357297 — intervention group
Group type: COMPARATOR
Intervention: 3 months anticoagulation
Number of subjects: 712
Study 3917304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 2 grams intramuscularly 30 minutes before operation and 2 grams every eight hours for two days postoperatively
Number of subjects: 52
Study 3917304 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 52
Study 3324612 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60
Study 3324612 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone plus fentanyl
Number of subjects: 60
Study 31722544 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive change in FV intake
Number of subjects: 168
Study 31722544 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive change in self-reported PA
Number of subjects: 168
Study 30371686 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 kg palpation stimulus
Number of subjects: 30
Study 30371686 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 kg palpation stimulus for 5 seconds
Number of subjects: 30
Study 30371686 — intervention group
Group type: COMPARATOR
Intervention: 0.5 kg palpation stimulus
Number of subjects: 30
Study 25300984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist) at a dose of 0.1 mmol/kg
Number of subjects: 229
Study 25300984 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol (ProHance) at a dose of 0.1 mmol/kg
Number of subjects: 229
Study 25300984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 229
Study 25300984 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol
Number of subjects: 229
Study 25300984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol and Gadoteridol
Number of subjects: 229
Study 23437796 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current cardioversion (DCC) successful patients (n = 39)
Number of subjects: 153
Study 23437796 — intervention group
Group type: COMPARATOR
Intervention: AF recurrence patients (n = 15)
Number of subjects: 153
Study 23437796 — intervention group
Group type: COMPARATOR
Intervention: AF patients (n = 153)
Number of subjects: 153
Study 21701167 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor™ 1 g/day (DHA/EPA ratio 1.25:1.0)
Number of subjects: 30
Study 21701167 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor™ 2 g/day
Number of subjects: 30
Study 17905178 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 322
Study 17905178 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin (HI)
Number of subjects: 322
Study 16449511 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 102
Study 16449511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10702452 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% wt/vol + sufentanil 0.75 microg/mL
Number of subjects: 120
Study 10702452 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% wt/vol + sufentanil 1.0 microg/mL
Number of subjects: 120
Study 10702452 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.2% wt/vol
Number of subjects: 120
Study 10702452 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% wt/vol + sufentanil 0.5 microg/mL
Number of subjects: 120
Study 9101388 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically supervised exercise training program for 6 months
Number of subjects: 171
Study 7645792 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT, n = 12)
Number of subjects: 29
Study 7645792 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA, n = 9)
Number of subjects: 29
Study 7645792 — intervention group
Group type: EXPERIMENTAL
Intervention: PRemedication with benzodiazepine (PR, n = 8)
Number of subjects: 29
Study 7645792 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (all treatments)
Number of subjects: 29
Study 2936766 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam taken one hour before a meal
Number of subjects: 18
Study 2936766 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam taken with a meal
Number of subjects: 18
Study 2936766 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam taken one hour after a meal
Number of subjects: 18
Study 2936766 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting conditions)
Number of subjects: 18
Study 30183739 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 108
Study 30183739 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture‐based classroom (control)
Number of subjects: 108
Study 26564381 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 1839
Study 26564381 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1839
Study 25156397 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors' use of openness techniques
Number of subjects: 44
Study 25156397 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors' use of awareness techniques
Number of subjects: 44
Study 25156397 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors' use of activation techniques
Number of subjects: 44
Study 23253298 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sealant patch (CSP) plus standard treatment
Number of subjects: 70
Study 23253298 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 70
Study 20458443 — intervention group
Group type: EXPERIMENTAL
Intervention: hMSH2 gIVS12-6T/C polymorphism
Number of subjects: 96
Study 20458443 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy (cisplatin or carboplatin)
Number of subjects: 96
Study 18766034 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive digital education aid
Number of subjects: 133
Study 18766034 — intervention group
Group type: COMPARATOR
Intervention: Routine assessment and education
Number of subjects: 133
Study 15943543 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group receiving monetary vouchers for CO levels of 8 ppm or less
Number of subjects: 20
Study 15943543 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent group receiving vouchers regardless of CO level
Number of subjects: 20
Study 15943543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 20
Study 15943543 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study 25327732 — intervention group
Group type: EXPERIMENTAL
Intervention: YAZ (drospirenone 3 mg and ethinylestradiol 20 microg)
Number of subjects: 187
Study 25327732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 25327732 — intervention group
Group type: EXPERIMENTAL
Intervention: YAZ
Number of subjects: 187
Study 10362048 — intervention group
Group type: EXPERIMENTAL
Intervention: N-isobutyrylcysteine (NIC) 300 mg b.i.d. for 24 weeks
Number of subjects: 637
Study 10362048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 10362048 — intervention group
Group type: EXPERIMENTAL
Intervention: N-isobutyrylcysteine (NIC)
Number of subjects: 637
Study 7595717 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim 5 micrograms/kg/d by once‐daily injection from day 4 to day 13
Number of subjects: 48
Study 7595717 — intervention group
Group type: COMPARATOR
Intervention: placebo (vehicle)
Number of subjects: 48
Study 7595717 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 48
Study 7595717 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 2406695 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant stimulation followed by physical therapy
Number of subjects: 48
Study 2406695 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental physical therapy
Number of subjects: 48
Study 7425833 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of phenytoin orally the evening before and on the morning of the operation
Number of subjects: 90
Study 7425833 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of phenytoin orally the evening before and on the morning of the operation
Number of subjects: 90
Study 7425833 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 90
Study 31383723 — intervention group
Group type: COMPARATOR
Intervention: Standard letter (general information)
Number of subjects: 7540
Study 31383723 — intervention group
Group type: COMPARATOR
Intervention: Descriptive norms letter (peer comparisons)
Number of subjects: 7540
Study 31383723 — intervention group
Group type: COMPARATOR
Intervention: Injunctive norms letter (appeal to authority)
Number of subjects: 7540
Study 31383723 — intervention group
Group type: COMPARATOR
Intervention: Combination norms letter (both social norms)
Number of subjects: 7540
Study 30286737 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct delivery of an HIV self-test
Number of subjects: 1382
Study 30286737 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of a coupon for an HIV self-test at nearby health clinics
Number of subjects: 1382
Study 30286737 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing services
Number of subjects: 1382
Study 27099248 — intervention group
Group type: EXPERIMENTAL
Intervention: High amino acid intake (Imm‐RDI)
Number of subjects: 168
Study 27099248 — intervention group
Group type: COMPARATOR
Intervention: Low amino acid intake (Inc‐AAs)
Number of subjects: 168
Study 27099248 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion (SMOF)
Number of subjects: 168
Study 27099248 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 168
Study 25262617 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocate(®) (2.5% moxidectin+10% imidacloprid) applied monthly, biweekly, or weekly
Number of subjects: 58
Study 25262617 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin (IVR) at 500 μg/kg daily
Number of subjects: 58
Study 25262617 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocate(®) (2.5% moxidectin+10% imidacloprid)
Number of subjects: 58
Study 25262617 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 58
Study 22709744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (150 mg to 300 mg twice a day, adjusted based on creatinine clearance and plasma levels)
Number of subjects: 405
Study 22709744 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dosing according to current practice guidelines)
Number of subjects: 405
Study 20067626 — intervention group
Group type: COMPARATOR
Intervention: Standard printed PA educational materials provided by the Canadian Diabetes Association (Group 1/control group)
Number of subjects: 287
Study 20067626 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard printed PA educational materials, pedometers, a log book, and printed PA information matched to individuals' PA stage of readiness provided every 3 months (Group 2)
Number of subjects: 287
Study 20067626 — intervention group
Group type: EXPERIMENTAL
Intervention: PA telephone counseling protocol matched to PA stage of readiness and tailored to personal characteristics, in addition to the materials provided in Groups 1 and 2 (Group 3)
Number of subjects: 287
Study 20067626 — intervention group
Group type: COMPARATOR
Intervention: Group 2 and Group 3 relative to Group 1
Number of subjects: 287
Study 20067626 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical (biomarkers) and health‐related quality of life assessments
Number of subjects: 287
Study 17336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 946
Study 17336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 946
Study 17336514 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 946
Study 15932790 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (800 IU/day)
Number of subjects: 34
Study 15932790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 34
Study 12205728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 40
Study 12205728 — intervention group
Group type: COMPARATOR
Intervention: Target-controlled propofol with fentanyl
Number of subjects: 40
Study 9839841 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 10
Study 9839841 — intervention group
Group type: COMPARATOR
Intervention: Overground running
Number of subjects: 10
Study 7994785 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Adriamycin (group A)
Number of subjects: 299
Study 7994785 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg epirubicin (group B)
Number of subjects: 299
Study 7994785 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pirarubicin (group C)
Number of subjects: 299
Study 7994785 — intervention group
Group type: COMPARATOR
Intervention: PS alone (group D, control)
Number of subjects: 299
Study 2726146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (300 USP units)
Number of subjects: 40
Study 2726146 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 30021178 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Unification Program (FUP) plus housing advocacy
Number of subjects: 89
Study 30021178 — intervention group
Group type: COMPARATOR
Intervention: Housing advocacy alone
Number of subjects: 89
Study 26940547 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide treatment
Number of subjects: 0
Study 26940547 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based treatment
Number of subjects: 0
Study 24831368 — intervention group
Group type: EXPERIMENTAL
Intervention: Single burr hole
Number of subjects: 254
Study 24831368 — intervention group
Group type: COMPARATOR
Intervention: Double burr hole
Number of subjects: 254